The ADA’s Precision Medicine in Diabetes Initiative aims to tap into the potential of individualized medicine to improve the lives of people with diabetes. Genetic testing is one component of this strategy to better understand the disease and refine diagnostics. Rinki Murphy, MBChB, FRACP, PhD, and other experts will discuss why endotypes matter in achieving…

Managing foot care is a challenge people living with diabetes face on a daily basis. David G. Armstrong, DPM, MD, PhD, and other panelists will present approaches providers can implement to help their patients living with diabetes get ahead of foot injuries and improve foot health.

Carrying extra weight exacerbates diabetes and can lead to a variety of metabolic and biomechanical complications. In SURMOUNT 2, a GLP-1/GIP dual receptor agonist led to weight loss in patients with both obesity and type 2 diabetes to an extent previously unseen. Investigators including W. Timothy Garvey, MD, will present trial results at the Scientific…

Since the publication of the Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes in 2021, the applicability of remission as a realistic treatment goal has evolved. A panel including Hertzel C. Gerstein, MD, MSc, FRCPC, will discuss the concept of remission in diabetes and its potential in research and patient care.

Experts including Aimee Afable, PhD, MPH, will discuss the growing risk of diabetes in populations that immigrate to the U.S. and what may be leading to those risk factors. Discussions will include the challenges of adapting programs and approaches in treating and mitigating diabetes to meet the needs of culturally distinct communities.

Last fall, the U.S. Food and Drug Administration approved teplizumab as the first disease-modifying therapy in type 1 diabetes. Experts including Stephen E. Gitelman, MD, will present insights from studies of teplizumab and other agents, including abatacept and hydroxychloroquine, that have provided road maps to help delay the onset of disease.

People with diabetes are at risk for retinopathy. Ward Fickweiler, MD, will discuss research exploring the relationship between the presence of age-related macular degeneration and diabetic retinopathy severity in people with type 1 diabetes. Other panelists will discuss glucose management, prior cerebrovascular disease, and autonomous artificial intelligence diabetic eye exams.